Bavar­i­an Nordic nabs EU ap­proval for mon­key­pox vac­cine as WHO de­clares glob­al health emer­gency

As the WHO de­clared the mon­key­pox out­break to be a glob­al health emer­gency, Bavar­i­an Nordic ob­tained an ex­pand­ed Eu­ro­pean la­bel for its small­pox vac­cine to in­clude the surg­ing virus.

The move comes rough­ly a month af­ter the biotech filed for a la­bel ex­pan­sion, and af­ter sev­er­al coun­tries on the con­ti­nent, and else­where, se­cured their own sup­ply deals for the shot. Bavar­i­an Nordic has said it’s seen “over­whelm­ing” in­ter­est in the vac­cine, and its stock price $BVRNY has fol­lowed in short or­der — shares are up 124% since the first mon­key­pox case was de­tect­ed on May 6.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN